Table 2

Occurrence of primary and secondary end points and unadjusted and adjusted HRs by clopidogrel vs aspirin

Clopidogrel, N=384Aspirin, N=1500Unadjusted HR (95% CI)p ValueAdjusted HR (95% CI)p Value
Primary outcome
 MACE91 (23.7%)570 (38.0%)0.54 (0.43 to 0.68)<0.0010.54 (0.43 to 0.68)<0.001
Secondary outcomes
 Any recurrent stroke81 (21.1%)520 (34.7%)0.53 (0.42 to 0.67)<0.0010.54 (0.42 to 0.69)<0.001
 Ischaemic stroke75 (19.5%)470 (31.3%)0.54 (0.43 to 0.70)<0.0010.55 (0.43 to 0.71)<0.001
 Intracranial haemorrhage6 (1.6%)50 (3.3%)0.41 (0.18 to 0.96)0.0410.40 (0.17 to 0.97)0.041
 Fatal stroke10 (2.6%)52 (3.5%)0.71 (0.36 to 1.40)0.3270.76 (0.38 to 1.53)0.443
 Myocardial infarction10 (2.6%)50 (3.3%)0.65 (0.33 to 1.28)0.2080.50 (0.24 to 1.05)0.067
 All-cause mortality64 (16.7%)229 (15.3%)0.93 (0.71 to 1.23)0.6180.97 (0.73 to 1.30)0.853
 MACE+ all-cause mortality155 (40.4%)799 (53.3%)0.66 (0.55 to 0.78)<0.0010.66 (0.55 to 0.78)<0.001
  • Model was adjusted for baseline age, gender, hypertension, diabetes, prior stroke, prior ischaemic heart disease, hyperlipidaemia, gastrointestinal bleeding or peptic ulcer, Charlson index, statin use, other antiplatelet drugs use, ACE inhibitors or angiotensin receptor blockers use, calcium channel blockers use and diuretics use during follow-up period.

  • MACE, major adverse cardiovascular event (composite of stroke and myocardial infarction).